Analysis: Shire PLC (ADR) (NASDAQ:SHPG) Price Target Change Today
In an analyst note sent to investors and clients by JP Morgan on Friday morning, the firm, Shire PLC (ADR) (NASDAQ:SHPG), had their target price cut to $275.00. Analusts presently have a solid “Overweight” rating on the stock.
From a total of 12 analysts covering Shire plc (ADR) (NASDAQ:SHPG) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 4 a ”Hold”. This means that 69% of the ratings are positive. The highest target price is $325 while the lowest target price is $221. The mean of all analyst targets is $268.83 with a 31.21% above today’s ($205.78) stock price. Shire plc (ADR) was the topic of 14 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Leerink Swann upgraded shares on November 17 to “Outperform” rating. RBC Capital Markets maintained SHPG stock in a recent report from October 26 with “Sector Perform” rating. Finally, Barclays Capital upgraded the stock to “Overweight” rating in a report issued on a September 21.
The stock increased 1.07% or $2.17 on December 4, striking $205.78. Approximately shares of stock traded hands. Shire PLC (ADR) (NASDAQ:SHPG) has declined 15.67% since May 4, 2015 and is downtrending. It has underperformed by 14.60% the S&P500.
Shire plc is a biopharmaceutical company. The company has a market cap of $40.40 billion. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.32 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.
According to Zacks Investment Research, “Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)” Get a free copy of the Zacks research report on Shire PLC (ADR) (SHPG).